Neutrophil–Platelet and Monocyte–Platelet Aggregates in COVID-19 Patients

Alexandre Le Joncour1,2,© Lucie Biard3 Mathieu Vautier1,2 Helene Bugaut1,2 Arsene Mekinian4 Georgina Maalouf1,2 Matheus Vieira1,2 Anne-Geneviève Marcelin5 Michelle Rosenzwajg6 David Klatzmann6 Jean-Christophe Corvol7 Olivier Paccoud8 Aude Carillion9 Joe-Elie Salem10 Patrice Cacoub1,2 Yacine Boulaftali11 David Saadoun1,2

1 Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Universités, Paris, France
2 Centre National de Référence Maladies Autoinflammatoires Rares et de l’Amylose inflammatoire, Paris, France
3 Department of Biostatistics and Medical Information, CRESS UMR 1153, INSERM, ECSTREA Team, Saint-Louis University Hospital, AP-HP, University of Paris, Paris, France
4 Service de Médecine Interne et Inflammation-Inmunopathology-Biotherapy Department (DMU I3), Hôpital Saint-Antoine, APHP, Sorbonne Université, Paris, France
5 Department of Virology, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique (IPESP), Groupe Hospitalier Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France
6 Sorbonne Université-INSERM UMR959, Immunology-Immunopathology-Immunotherapy (I3), Biotherapy (CIC-BTi), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France

Address for correspondence Alexandre Le Joncour, Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, F-75013, Paris, France (e-mail: yacine.boulaftali@inserm.fr; alexandre.lejoncour@aphp.fr).

7 Department of Neurology, Clinical Investigation Center for Neurosciences, Inserm, CNRS, Paris Brain Institute - ICM, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France
8 Department of Infectious and tropical disease, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
9 Department of Anesthesiology and Critical Care Medicine, Institut de Cardiologie, UMR INSERM 1166, IHU ICAN, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
10 CIC (CIC-1901), CLIP2 Caliée, Department of Pharmacology and Clinical Investigation Center, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
11 INSERM UMR 1148 -LVTS, Laboratory for Vascular Translational Science Université de Paris GH Bichat-Claude Bernard, Paris, France


Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the world. Besides severe pneumonia with acute respiratory distress syndrome (ARDS), it has been more recently highlighted that SARS-CoV-2 could predispose to thrombotic disease, both in venous and arterial circulations.1 Lung autopsy from severe COVID-19 patients revealed high recruitment of innate immune cells including neutrophils and macrophages contributing to the cytokine storm as well as microthrombi.2 Given the central role of platelets in inflammation and thrombosis, and more specifically leucocyte-platelet aggregates that have been implicated in arterial and venous thrombosis, we aimed to explore neutrophil–platelet aggregate (NPA) and monocyte–platelet aggregate (MPA) in patients hospitalized in a medical ward for COVID-19 infection.

Data were collected from patients with COVID-19 participating in an open label, randomized, clinical trial testing sarilumab (400 mg) versus standard of care (SOC) conducted at the Pitié-Salpêtrière Hospital. Patients with moderate or severe pneumopathy according to the World Health Organization Criteria of severity of COVID pneumopathy and positive to SARS-CoV-2 real-time reverse transcriptase-polymerase chain reaction assay from nasal swabs were included in this study. Moderate cases were classified as clinical symptoms associated with a maximum of 3 L/min of oxygen. Severe cases were defined as patients requiring more than 3 L/min of oxygen. The study received Paris VI ethical committee approval, conforming to the principles of the Declaration of Helsinki, and is registered as NCT04341870. All patients gave informed consent.

Whole blood samples were collected by venipuncture into EDTA vacutainers rapidly diluted in 3.2% sodium citrate. Cells were stained less than 3 hours after venipuncture using PerFix-nC (Beckman Coulter) according to the manufacturer’s instructions and using the following antibodies: fluorophore-labeled anti-CD45, anti-CD15, anti-CD16, anti-CD14, anti-CD163, and anti-CD68. Control samples were stained with fluorophore-labeled anti-CD45 but no anti-CD15, anti-CD16, anti-CD14, anti-CD163, and anti-CD68.
anti-CD14, and anti-CD41b. Acquisition was performed using a Navios cytometer and analyzed with Kaluza software (Beckman Coulter). Gating strategy is shown in Fig. 1A.

Continuous variables were presented as median (interquartile range) or mean (±standard error of mean) and compared using the Mann–Whitney and Kruskal–Wallis tests with Dunn’s correction for multiple comparisons or the Wilcoxon test when appropriate. Categorical variables were presented as counts (percent) and compared using Fisher’s exact test. Analyses were computed using GraphPad Prism (GraphPad Software, San Diego, United States).

Twenty-seven patients were included, 14 (52%) were males with a median age of 71 years. Thirteen patients were classified with “moderate” and 14 with “severe” COVID-19 pneumonia. Patients with severe disease were more frequently males compared with patients with moderate disease: 10/14

Fig. 1 NPA and MPA in COVID-19 patients. (A) Gating strategy and representative dot-plots of flow cytometry analysis. (B) Levels of NPA and MPA according to disease severity. (C) Correlation of NPA and MPA with CRP and IL-6. (D) Levels of NPA and MPA before and after treatment with an anti-IL-6 receptor or SOC. Data are shown as means ± SEM. For statistical analyses, Kruskal–Wallis, Spearman, and Wilcoxon tests were used; *p < 0.05, **p < 0.01, ***p < 0.001. CRP, C-reactive protein; IL-6, interleukin-6; MPA: monocyte–platelet aggregate; NPA, neutrophil–platelet aggregate; SEM, standard error of mean; SOC, standard of care.
Levels (treated with sarilumab showed a decrease in NPA and MPA with moderate disease (25.2% ± 17.4 vs. 14.1% ± 10.8–18.2), p = 0.001 and 33.6% ± 20.4–46.9 vs. 18.4% ± 13.8–20.1, p = 0.001, respectively) (Fig. 1B). We report here the first evidence of platelet and leukocyte aggregates in COVID-19 suggesting that platelets are in a preactivated state and can contribute to the microthrombotic complication in severe patients. In agreement with our observation, MPAs were found to be associated with the development of ARDS in a study by Abdulnour et al. Moreover, in a mouse model of acute lung injury, NPs were found to exert a critical role.

Next, we pointed out a positive correlation between levels of NPA and MPA and CRP (r = 0.658, p = 0.005 and r = 0.563, p = 0.002, respectively) and IL-6 (r = 0.628, p = 0.01 and r = 0.694, p = 0.003) (Fig. 1C). Yan et al. showed in a model of colitis that IL-6 was the key mediator of NPs suggesting that IL-6 is a suitable target to manage thromboinflammatory diseases.

Lastly, we investigated the impact of sarilumab (anti-IL-6 receptor) in NPA and MPA. Leukocyte–platelet aggregates were analyzed at baseline and 7 days after a single infusion of sarilumab on top of SOC (n = 15) or SOC without sarilumab (n = 5) for which samples were available. All but three patients treated with sarilumab showed a decrease in NPA and MPA levels (p = 0.002 for both) (Fig. 1D). This reduction of MPA and NPA may have contributed to the better outcome observed under sarilumab or other anti-IL-6 therapies that have been proposed to tip down the cytokine storm of COVID-19 pneumonia. Anti-IL-6 therapies are known to diminish neutrophil, platelets, and monocytes. Overall, our study suggests that targeting the cytokine storm may reduce platelet/leukocyte complexes which can alleviate the thrombotic/microthrombotic complications in severe COVID-19 patients.

In conclusion, NPA and MPA are increased and correlated with both inflammation and severity in COVID-19 patients. Leukocyte–platelet aggregates may be implicated in the pathophysiology of COVID-19. Targeting the IL-6 pathway may result in a reduction of leukocyte–platelet aggregates.

Authors’ Contributions

Conflict of Interest
None declared.

Acknowledgments
We thank Basma Abdi, Cathia Soulue, and Elisa Teysou for their technical assistance. We thank Louis-Marie Bobay for editing the manuscript.

References

NPA and MPA in COVID-19 Patients  Le Joncour et al.